ABSTRACT
BBG2Na is a recombinant protein, composed in part of carrier protein BB and of the central conserved domain of the attachment glycoprotein G of human respiratory syncytial virus (HRSV) subgroup A. This protein is a potent vaccine candidate against HRSV. G2Na contains several contiguous B-cell epitopes, occupying sequential positions in the linear sequence of the protein. One of the epitopes contains four cysteines that are completely conserved in known strains of HRSV and form a 'cysteine noose' motif. In this study, we analysed circular dichroism (CD) spectra of BBG2Na and its B-cell epitopes. We also used NMR and molecular dynamics simulations to determine the three-dimensional structure of the cysteine noose domain. We observed significant structural differences related to the length of peptides containing the cysteine noose. These differences show good correlation with the immunogenic activity of the peptides. It is shown that a single Val(171) addition induces a pronounced structure stabilization of the cysteine noose peptide G4a (1-4/2-3) (residues 172-187), which is associated with a 100-fold increase in its antigenicity vis-à-vis a G-protein specific monoclonal antibody.
Subject(s)
Antigens, Viral/chemistry , Respiratory Syncytial Virus Vaccines/immunology , Respiratory Syncytial Virus, Human/chemistry , Respiratory Syncytial Virus, Human/immunology , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/immunology , Antigens, Viral/immunology , Circular Dichroism , Humans , Magnetic Resonance Spectroscopy , Protein Conformation , Respiratory Syncytial Virus Vaccines/chemistry , Structure-Activity Relationship , Vaccines, Subunit/chemistry , Vaccines, Subunit/immunologyABSTRACT
Administration of vaccines by the nasal route has recently proven to be one of the most efficient ways for inducing both mucosal and systemic antibody responses in experimental animals. Our results demonstrate that P40, a well-defined outer membrane protein A from Klebsiella pneumoniae, is indeed a carrier molecule suitable for nasal immunization. Using fragments from the respiratory syncytial virus subgroup A (RSV-A) G protein as antigen models, it has been shown that P40 is able to induce both systemic and mucosal immunity when fused or coupled to a protein or a peptide and administered intranasally (i.n.) to naive or K. pneumoniae-primed mice. Confocal analyses of nasal mucosa-associated lymphoid tissue after i.n. instillation of P40 showed that this molecule is able to cross the nasal epithelium and target CD11c-positive cells likely to be murine dendritic cells or macrophages. More importantly, this targeting of antigen-presenting cells following i.n. immunization with a subunit of the RSV-A molecule in the absence of any mucosal adjuvant results in both upper and lower respiratory tract protection against RSV-A infection.
Subject(s)
Adjuvants, Immunologic , Antigen-Presenting Cells/immunology , Antigens, Viral/immunology , Bacterial Outer Membrane Proteins/immunology , Klebsiella pneumoniae/immunology , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Vaccines/immunology , Vaccines, Synthetic/immunology , Viral Proteins/immunology , Administration, Intranasal , Amino Acid Sequence , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/metabolism , Biological Transport , Disease Models, Animal , Female , Humans , Immunity, Mucosal , Lymphoid Tissue/immunology , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Nasal Mucosa/immunology , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/metabolism , Respiratory Syncytial Virus Infections/immunology , Vaccination/methodsABSTRACT
Human respiratory syncytial virus (hRSV) is a major pathogen responsible for bronchiolitis and severe pulmonary disease in very young children, immunodeficient patients and the elderly. BBG2Na, a recombinant chimeric protein produced in Escherichia coli, is a promising subunit vaccine candidate against this respiratory pathogen, composed of G2Na, the central domain of RSV G glycoprotein, and BB, an albumin binding domain of streptococcal protein G. BBG2Na has a basic isoelectric point (pI 9.3) and as expected, is strongly adsorbed by aluminium phosphate (AP). Surprisingly, BBG2Na is also strongly adsorbed by aluminium hydroxide (AH), which normally binds molecules with acidic isoelectric points. This behaviour was unexpected according to the well established adsorption model of Hem and co-workers. Our observations may be explained by the bipolar two-domain structure of the BBG2Na chimera which is not reflected by the global basic isoelectric point of the whole protein: the BB domain has an acidic isoelectric point (pI 5.5) and the G2Na domain a highly basic one (pI 10.0). Importantly, formulation in either aluminium salt resulted in equally high immunogenicity and protective efficacy against RSV in mice. From a physicochemical point of view, this unique property of BBG2Na makes it eminently suitable for combination to either paediatric or elderly multivalent AH- or AP-containing vaccines already in the market or in development.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Aluminum Compounds/administration & dosage , Aluminum Hydroxide/administration & dosage , Phosphates/administration & dosage , Respiratory Syncytial Virus, Human/immunology , Vaccines, Synthetic/immunology , Viral Vaccines/immunology , Adsorption , Amino Acid Sequence , Animals , Buffers , Ethylene Glycol/pharmacology , Hydrogen-Ion Concentration , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Vaccines, Subunit/immunologyABSTRACT
Several cytotoxic T lymphocyte peptide-based vaccines against hepatitis B, human immunodeficiency virus and melanoma were recently studied in clinical trials. One interesting melanoma vaccine candidate alone or in combination with other tumor antigens, is the decapeptide ELA. This peptide is a Melan-A/MART-1 antigen immunodominant peptide analog, with an N-terminal glutamic acid. It has been reported that the amino group and gamma-carboxylic group of glutamic acids, as well as the amino group and gamma-carboxamide group of glutamines, condense easily to form pyroglutamic derivatives. To overcome this stability problem, several peptides of pharmaceutical interest have been developed with a pyroglutamic acid instead of N-terminal glutamine or glutamic acid, without loss of pharmacological properties. Unfortunately compared with ELA, the pyroglutamic acid derivative (PyrELA) and also the N-terminal acetyl-capped derivative (AcELA) failed to elicit cytotoxic T lymphocyte (CTL) activity. Despite the apparent minor modifications introduced in PyrELA and AcELA, these two derivatives probably have lower affinity than ELA for the specific class I major histocompatibility complex. Consequently, in order to conserve full activity of ELA, the formation of PyrELA must be avoided. Furthermore, this stability problem is worse in the case of clinical grade ELA, produced as an acetate salt, like most of the pharmaceutical grade peptides. We report here that the hydrochloride salt, shows higher stability than the acetate salt and may be suitable for use in man. Similar stability data were also obtained for MAGE-3, another N-terminal glutamic acid containing CTL peptide in clinical development, leading us to suggest that all N-terminal glutamic acid and probably glutamine-containing CTL peptide epitopes may be stabilized as hydrochloride salts.
Subject(s)
Antigens, Neoplasm , Glutamic Acid/chemistry , Isoantigens/metabolism , Melanoma/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Anion Exchange Resins , Cancer Vaccines/immunology , Cell Line/immunology , Cell Line/metabolism , Chromatography, High Pressure Liquid , Chromium/metabolism , Epitopes, T-Lymphocyte , Granulocytes , Humans , Immunization , Mice , Neoplasm Proteins/chemistry , Neoplasm Proteins/immunology , Neoplasm Proteins/metabolism , Peptides/chemical synthesis , Peptides/chemistry , Peptides/metabolism , Spectrometry, Mass, Electrospray IonizationABSTRACT
Respiratory syncytial virus (RSV) is a major respiratory pathogen responsible for severe pulmonary disease. We have developed a parenterally administered vaccine, BBG2Na, which is currently in a phase III clinical trial. BBG2Na comprises residues 130--230 of RSV-A G protein (G2Na) fused to the BB carrier protein. In this study, we show that BBG2Na can be delivered by the nasal route and generates both mucosal and systemic antibody responses when co-administered with cholera toxin B or a newly described delivery system, zwittergent 3--14. We found that nasal BBG2Na administration protects against RSV challenge and does not induce lung immunopathology upon subsequent RSV challenge.
Subject(s)
Respiratory Syncytial Virus Vaccines/administration & dosage , Respiratory Syncytial Viruses/immunology , Administration, Intranasal , Animals , Antibodies, Viral/biosynthesis , Cholera Toxin/administration & dosage , Female , HN Protein/immunology , Humans , Immunity, Mucosal , Injections, Intramuscular , Mice , Mice, Inbred BALB C , Nasal Mucosa/drug effects , Nasal Mucosa/pathology , Quaternary Ammonium Compounds/administration & dosage , Quaternary Ammonium Compounds/toxicity , Vaccines, Subunit/administration & dosage , Viral Envelope ProteinsABSTRACT
We have developed and validated a process-specific immunoligand assay based on the Threshold system for the quantification of residual host cell proteins (HCPs) in a recombinant subunit vaccine candidate against the human respiratory syncytial virus (hRSV). The industrial process of this vaccine produced in Escherichia coli, involved five chromatography steps for the production of clinical-grade batches. The clearance of non-product-related protein throughout the purification process was documented by the evaluation of the HCP content in the chromatographic fractions at each step of the downstream processing. The assay had a detection limit of 0.5 ng/ml of HCP equivalent to 10 parts per million (ppm). The quantification limit was 1.3 ng/ml of HCP, giving a sensitivity range of the assay of 10 to 30 ppm. To our knowledge, this is the first sensitive HCP assay reported for a vaccine.
Subject(s)
Immunoassay/methods , Respiratory Syncytial Viruses/genetics , Respiratory Syncytial Viruses/immunology , Viral Vaccines/analysis , Antibodies, Bacterial , Antibody Specificity , Bacterial Proteins/analysis , Bacterial Proteins/immunology , Drug Contamination , Escherichia coli/genetics , Escherichia coli/immunology , Humans , Immunoassay/statistics & numerical data , In Vitro Techniques , Sensitivity and Specificity , Vaccines, Subunit/analysis , Vaccines, Synthetic/analysisABSTRACT
The recent identification of tumor Ags as potential vaccines has prompted the search for efficient adjuvants and delivery systems, especially in the case of peptide-based vaccination protocols. Here, we investigated the adjuvant potential of the recombinant 40-kDa outer membrane protein of Klebsiella pneumoniae (P40) for specific CTL induction. We studied the CTL response induced in HLA-A*0201/K(b) transgenic mice immunized with peptides derived from two melanoma-associated differentiation Ags, the HLA-A*0201-restricted decapeptide Melan-A(26--35) substituted at position 2 and the K(b)-restricted tyrosinase-related protein 2(181--188) T cell epitope. We found that both peptides are able to generate a specific CTL response when mixed with the protein in the absence of conventional adjuvant. This CTL response is a function of the amount of P40 used for immunization. Moreover, the CTL response generated against the tyrosinase-related protein 2(181-188) peptide in presence of P40 is associated with tumor protection in two different experimental models and is independent of the presence of CD4(+) T lymphocytes. Thus, the recombinant bacterial protein P40 functions as a potent immunological adjuvant for specific CTL induction.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Bacterial Outer Membrane Proteins/immunology , Cancer Vaccines/chemical synthesis , Cytotoxicity, Immunologic/immunology , Epitopes, T-Lymphocyte/immunology , Klebsiella pneumoniae/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Adjuvants, Immunologic/chemical synthesis , Animals , Antigens, Neoplasm/administration & dosage , Antigens, Neoplasm/immunology , Bacterial Outer Membrane Proteins/administration & dosage , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/administration & dosage , Cancer Vaccines/immunology , Drug Combinations , Immunotherapy, Active/methods , Injections, Subcutaneous , Intramolecular Oxidoreductases/administration & dosage , Intramolecular Oxidoreductases/immunology , Lymphocyte Depletion , MART-1 Antigen , Macromolecular Substances , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Melanoma, Experimental/prevention & control , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Neoplasm Proteins/administration & dosage , Neoplasm Proteins/immunology , Neoplasm Transplantation , Peptide Fragments/administration & dosage , Peptide Fragments/chemical synthesis , Titrimetry , Tumor Cells, Cultured/transplantationABSTRACT
Respiratory syncytial virus (RSV) is an important respiratory pathogen in man, against which no vaccine is available. However, recent evidence suggests that antibodies to the RSV F and G proteins may play an important role in disease prevention. We previously demonstrated that BBG2Na, a subunit vaccine candidate including residues 130-230 of the Long strain G protein, protects rodents against RSV challenge. Using a panel of monoclonal antibodies (MAb) and synthetic peptides, five linear B cell epitopes were identified that mapped to residues 152-163, 165-172, 171-187 (two over-lapping epitopes) and 196-204. Antibody passive transfer and peptide immunisation studies revealed that all were protective. Pepscan analyses of anti-RSV-A and BBG2Na murine polyclonal sera suggested stronger immunogenicity of some protective epitopes (protectopes) in the context of BBG2Na compared with live virus. However, all the identified murine B cell protectopes were conserved in RSV seropositive humans. Should these protectopes correspond with protection in humans, BBG2Na may constitute a very interesting vaccine candidate against RSV.
Subject(s)
B-Lymphocytes/immunology , Respiratory Syncytial Viruses/immunology , Viral Proteins/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal , Antibodies, Viral , Antigens, Viral/genetics , Epitope Mapping , Epitopes , Humans , Immunization, Passive , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Respiratory Syncytial Viruses/genetics , Vaccines, Subunit/genetics , Vaccines, Subunit/pharmacology , Viral Proteins/genetics , Viral Vaccines/genetics , Viral Vaccines/pharmacologyABSTRACT
The decapeptide ELA (ELAGIGILTV), a Melan-A/MART-1 antigen immunodominant peptide analogue, is an interesting melanoma vaccine candidate alone or in combination with other tumour antigens. P40, the recombinant outer membrane protein A of Klebsiella pneumoniae (kpOmpA), was recently shown to target dendritic cells and to induce peptide-specific CTLs. Here we investigated the adjuvant role of P40 mixed or chemically conjugated to ELA. This compound is an N-terminal glutamic acid-containing peptide. However, it has been reported that the amino group and the gamma-carboxylic group of glutamic acids easily condense to form pyroglutamic derivatives. Usually, to overcome this stability problem, peptides of pharmaceutical interest were developed with a pyroglutamic acid instead of N-terminal glutamic acid, without loss of pharmacological properties. Unfortunately, the pyroglutamic acid derivative (PyrELA) as well as the N-terminal acetyl capped derivative (AcELA) failed to elicit CTL activity when mixed with P40 adjuvant protein. Despite the apparent minor modifications introduced by PyrELA and AcELA, these two derivatives have probably lower affinity than ELA for the class I Major Histocompatibility Complex. Furthermore, this stability problem is worse in the case of clinical grade ELA, produced as an acetate salt, like most of the pharmaceutical grade peptides. We report here that the hydrochloride shows a higher stability than the acetate and may be suitable for use in man.
Subject(s)
Cancer Vaccines/immunology , Melanoma/therapy , T-Lymphocytes, Cytotoxic/immunology , Animals , Cancer Vaccines/chemistry , Cancer Vaccines/therapeutic use , Chromatography, High Pressure Liquid , Melanoma/immunology , Mice , Mice, Transgenic , Models, MolecularABSTRACT
Respiratory syncytial virus is one of the major respiratory pathogens for infants and immunocompromized children. With the exception of young children, all the population has encountered RSV and is seropositive. Recent reports have demonstrated however that the virus also affects the elderly and represents a major cause of illness associated with an excess of morbidity and mortality. We have generated a recombinant RSV vaccine, BBG2Na, which is highly protective in rodents against RSV infection. The aim of this study was to evaluate the ability of the vaccine to increase anti-RSV protection in RSV-primed mice and to characterize the induced immune responses. Immunization with BBG2Na increased the anti-RSV-A serum antibody titers of RSV-primed mice with induction of both IgG1 and IgG2a antibodies attesting for a mixed Th response. Moreover, the level of the induced anti-G2Na antibodies was greater in seropositive mice. Finally, sera from RSV-primed mice displayed a higher protective efficacy after transfer into naive mice following subsequent immunization with BBG2Na than sera of mice immunized with RSV-A only. Our results demonstrate that BBG2Na is immunogenic and increases the protective efficacy of serum antibodies in RSV-primed mice; they support the possibility of performing clinical trials in the seropositive human population.
Subject(s)
Antibodies, Viral/biosynthesis , Antigens, Viral/immunology , Bacterial Proteins/immunology , HN Protein , Respiratory Syncytial Viruses/immunology , Viral Envelope Proteins/immunology , Viral Fusion Proteins/immunology , Viral Proteins/immunology , Viral Vaccines/immunology , Animals , Cytokines/biosynthesis , Enzyme-Linked Immunosorbent Assay , Epitope Mapping , Humans , Mice , Recombinant Proteins/immunology , Respiratory Syncytial Viruses/isolation & purificationABSTRACT
We analyzed the protective mechanisms induced against respiratory syncytial virus subgroup A (RSV-A) infection in the lower and upper respiratory tracts (LRT and URT) of BALB/c mice after intraperitoneal immunization with a recombinant fusion protein incorporating residues 130 to 230 of RSV-A G protein (BBG2Na). Mother-to-offspring antibody (Ab) transfer and adoptive transfer of BBG2Na-primed B cells into SCID mice demonstrated that Abs are important for LRT protection but have no effect on URT infection. In contrast, RSV-A clearance in the URT was achieved in a dose-dependent fashion after adoptive transfer of BBG2Na-primed T cells, while it was abolished in BBG2Na-immunized mice upon in vivo depletion of CD4(+), but not CD8(+), T cells. Furthermore, the conserved RSV-A G protein cysteines and residues 193 and 194, overlapping the recently identified T helper cell epitope on the G protein (P. W. Tebbey et al., J. Exp. Med. 188:1967-1972, 1998), were found to be essential for URT but not LRT protection. Taken together, these results demonstrate for the first time that CD4(+) T cells induced upon parenteral immunization with an RSV G protein fragment play a critical role in URT protection of normal mice against RSV infection.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , HN Protein , Immunization , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Viruses/immunology , Respiratory Tract Infections/prevention & control , Viral Proteins/immunology , Adoptive Transfer , Animals , B-Lymphocytes/immunology , Female , Immunity, Maternally-Acquired , Mice , Mice, Inbred BALB C , Mice, SCID , Pregnancy , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/immunology , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Viruses/genetics , Respiratory Tract Infections/virology , T-Lymphocytes/immunology , Viral Envelope Proteins , Viral Proteins/administration & dosage , Viral Proteins/geneticsABSTRACT
Respiratory Syncytial Virus (RSV) is the most important cause of bronchiolitis and viral pneumonia in infants and young children. Approximately 100000 children are hospitalized in the USA each year as a result of RSV infections. During the research and development of subunit human Respiratory Syncytial Virus vaccines (hRSV), we have produced numerous synthetic peptides and recombinant proteins containing the four cysteines of the highly conserved central region of the G attachment protein. For several of these disulfide-containing peptides, all possible oxidized isomers were synthesized using various oxidation conditions and resulting in different ratios of isomers. Each isolated isomer was fully characterized by RP-HPLC, FZCE and ES-MS after purification by preparative RP-HPLC. The different cysteine pairings were unambiguously established after enzymatic digestion, LC-MS analysis and peptide microsequencing. These synthesis and analytical methods were developed for the characterization on one hand, of recombinant fusion protein BBG2Na which is currently being investigated in advanced clinical phases as a very promising vaccine candidate, and on the other hand, for peptides which were synthesized to be evaluated as conjugate vaccines or as immunochemical tools, after covalent coupling to carrier proteins. Furthermore, these studies allowed us to determine which of the different possible isomers was the most stable and probably the preferred form in native conditions. Finally, the different oxidation and analysis conditions, should be useful for disulfide pairing studies of other peptides and proteins having the same 'xCxxCxxxxxCxxxCx' framework, such as G proteins of non-human RSV strains, developed by other groups as veterinary vaccine candidates for example.
Subject(s)
HN Protein , Viral Proteins/chemistry , Amino Acid Sequence , Chromatography, High Pressure Liquid/methods , Disulfides/chemistry , Enzyme-Linked Immunosorbent Assay/methods , Glutaral/chemistry , Mass Spectrometry/methods , Molecular Sequence Data , Oxidation-Reduction , Peptide Mapping/methods , Protein Isoforms , Recombinant Proteins/chemical synthesis , Recombinant Proteins/chemistry , Respiratory Syncytial Viruses , Thermolysin/chemistry , Thermolysin/metabolism , Trypsin/chemistry , Trypsin/metabolism , Viral Envelope Proteins , Viral Proteins/chemical synthesis , Viral Proteins/metabolismABSTRACT
Respiratory Syncytial Virus (RSV) is the most important cause of bronchiolitis and viral pneumoniae in infants and young children. Approximately 100,000 children are hospitalized in the USA each year as a result of RSV infections. During the research and development of subunit human RSV vaccines, we have produced numerous synthetic peptides and recombinant proteins containing the four cysteines of the highly conserved central region of the G attachment protein. For several of these disulphide bridges containing peptides, all possible oxidizing isomers were synthesized using various oxidising conditions, resulting in different ratios of isomers. Each isolated isomer was fully characterized by RP-HPLC, FZCE and ES-MS after purification by preparative RP-HPLC. The different cysteine pairings were unambiguously established after enzymatic digestion, LC-MS analysis and peptide microsequencing. These synthetic and analytical methods were developed for the characterization of recombinant fusion protein BBG2Na which is currently investigated in clinical phase II and seems to be as a very promising vaccine candidate, and for peptides which were synthesized to be evaluated as conjugate vaccines or as immunochemical tools, after covalent coupling to carrier proteins. Furthermore, these studies allowed us to determine which of the different possible isomers was the most stable and probably the preferred form in native conditions. Finally, the different oxidising and analysis conditions, should be useful for disulphide pairing studies of other peptides and proteins having the same "xCxxCxxxxxCxxxCx" framework, such as G proteins of non-human RSV strains, developed for example as veterinary vaccine candidates.
Subject(s)
Disulfides/chemical synthesis , Respiratory Syncytial Virus, Human/chemistry , Viral Envelope Proteins/chemical synthesis , Chromatography, Liquid , Mass Spectrometry , Peptides/chemical synthesis , Peptides/immunology , Recombinant Proteins/chemical synthesis , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Respiratory Syncytial Virus, Human/immunology , Viral Envelope Proteins/immunology , Viral Vaccines/chemical synthesis , Viral Vaccines/chemistry , Viral Vaccines/immunologySubject(s)
Bacterial Outer Membrane Proteins/chemistry , Bacterial Outer Membrane Proteins/immunology , Klebsiella pneumoniae/chemistry , Klebsiella pneumoniae/immunology , Peptides/chemistry , Peptides/immunology , Polysaccharides, Bacterial/chemistry , Polysaccharides, Bacterial/immunology , Vaccines, Conjugate/chemistry , Vaccines, Conjugate/immunology , Animals , Carrier Proteins/chemistry , Chemical Phenomena , Chemistry, Physical , Enzyme-Linked Immunosorbent Assay , Escherichia coli/metabolism , Immunoglobulin G/biosynthesis , Immunoglobulin G/chemistry , Mice , Mice, Inbred BALB CABSTRACT
We have recently cloned a new protein, recombinant P40 (rP40). When tested in vivo after conjugation to a B-cell epitope, rP40 induces an important antibody response without the need for adjuvant. To characterize its potency, this carrier protein was coupled to a peptide derived from respiratory syncytial virus attachment G protein (G1'). After immunization of mice with the rP40-G1' conjugate, strong antipeptide antibodies were detected, whereas peptide alone was not immunogenic. To emphasize the carrier properties of rP40, a polysaccharide derived from Haemophilus influenzae type b (Hib) was coupled to it. Immunoglobulin G responses against the Hib polysaccharide were observed after coupling to rP40. Interestingly, an antipeptide antibody response was observed despite preexisting anti-rP40 antibodies generated by preimmunization with rP40. In addition, rP40 compares well with the reference carrier protein, tetanus toxoid (TT), since antibody responses of equal intensity were observed when a peptide or a polysaccharide was coupled to TT and rP40. Moreover, rP40 had advantages compared to TT; e.g., it induced a mixed Th1/Th2 response, whereas TT induced only a Th2 profile. Together, the results indicate that rP40 is a novel carrier protein with potential for use as an alternative carrier for human vaccination.
Subject(s)
Bacterial Outer Membrane Proteins/immunology , Carrier Proteins/immunology , HN Protein , Klebsiella pneumoniae/chemistry , Animals , Antibodies, Bacterial/blood , Bacterial Capsules , Female , Haemophilus Vaccines/immunology , Immunization , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Polysaccharides, Bacterial/immunology , Recombinant Proteins/immunology , Tetanus Toxin/immunology , Viral Envelope Proteins , Viral Proteins/immunologyABSTRACT
A recombinant fusion protein (BBG2Na) comprising the central conserved domain of the respiratory syncytial virus subgroup A (RSV-A) (Long) G protein (residues 130 to 230) and an albumin binding domain of streptococcal protein G was shown previously to protect mouse upper (URT) and lower (LRT) respiratory tracts against intranasal RSV challenge (U. F. Power, H. Plotnicky-Gilquin, T. Huss, A. Robert, M. Trudel, S. Stahl, M. Uhlén, T. N. Nguyen, and H. Binz, Virology 230:155-166, 1997). Panels of monoclonal antibodies (MAbs) and synthetic peptides were generated to facilitate dissection of the structural elements of this domain implicated in protective efficacy. All MAbs recognized native RSV-A antigens, and five linear B-cell epitopes were identified; these mapped to residues 152 to 163, 165 to 172, 171 to 187 (two overlapping epitopes), and 196 to 204, thereby covering the highly conserved cysteine noose domain. Antibody passive-transfer and peptide immunization studies revealed that all epitopes were implicated in protection of the LRT, but not likely the URT, against RSV-A challenge. Pepscan analyses of anti-RSV-A and anti-BBG2Na murine polyclonal sera revealed lower-level epitope usage within the central conserved region in the former, suggesting diminished immunogenicity of the implicated epitopes in the context of the whole virus. However, Pepscan analyses of RSV-seropositive human sera revealed that all of the murine B-cell protective epitopes (protectopes) that mapped to the central conserved domain were recognized in man. Should these murine protectopes also be implicated in human LRT protection, their clustering around the highly conserved cysteine noose region will have important implications for the development of RSV vaccines.
Subject(s)
Antigens, Viral/immunology , Epitopes, B-Lymphocyte/immunology , HN Protein , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus, Human/immunology , Viral Proteins/immunology , Animals , Antibodies, Monoclonal/immunology , Antibodies, Viral/immunology , Binding Sites , Disease Models, Animal , Epitope Mapping , Female , Humans , Mice , Mice, Inbred BALB C , Peptides/chemical synthesis , Peptides/immunology , Recombinant Fusion Proteins/immunology , Respiratory Syncytial Virus Infections/prevention & control , Viral Envelope ProteinsABSTRACT
The relative immunopathogenic potential of a recombinant fusion protein incorporating residues 130-230 of respiratory syncytial virus (RSV-A) G protein (BBG2Na), formalin-inactivated RSV-A (FI-RSV), and phosphate-buffered saline (PBS) was investigated in mice after immunization and RSV challenge. FI-RSV priming resulted in massive infiltration of B cells and activated CD4(+) and CD8(+) T lymphocytes in mediastinal lymph nodes (MLN) and lungs, where eosinophilia and elevated IFN-gamma, IL-2, -4, -5, -10, and -13 mRNA transcripts were also detected. PBS-primed mice showed only elevated pulmonary IL-2 and IFN-gamma mRNAs, while an activated CD8(+) T cell peak was detected in MLN and lungs. Cell infiltration also occurred in MLN of BBG2Na-immunized mice. However, there was no evidence of T cell, B cell, or granulocyte infiltration or activation in lungs, while transient transcription of Th1-type cytokine genes was evident. The absence of pulmonary infiltration is unlikely due to insufficient viral antigen. Thus, this recombinant fusion RSV G fragment does not prime for adverse pulmonary immunopathologic responses.
Subject(s)
HN Protein , Lung/immunology , Respiratory Syncytial Virus, Human/immunology , Viral Proteins/immunology , Animals , B-Lymphocytes/immunology , Cytokines/genetics , Female , Humans , Lymph Nodes/immunology , Mice , Mice, Inbred BALB C , RNA, Messenger , Recombinant Fusion Proteins/immunology , T-Lymphocytes/immunology , Tumor Cells, Cultured , Vaccination , Viral Envelope ProteinsABSTRACT
BBG2Na is a protein comprising residues 130-230 of the respiratory syncytial virus subgroup A (RSV-A) G protein (G2Na) fused to the albumin-binding domain of streptococcal G protein (BB). BBG2Na was cloned, expressed in Escherichia coli and renaturated. In rodent models, this subunit RSV vaccine adjuvanted in Alhydrogel induced specific antibodies and conferred protection to RSV infection. Comparison of the antibody production in a BALB/c mouse model revealed that BBG2Na induced a stronger and earlier G2Na antibody response than G2Na alone, without altering the IgG subclass distribution. To address the role of the BB part, we explored its carrier properties and showed that it is a Th dependent antigen, generating a more potent G2Na-specific B cell memory response and able to generate Th cells that provide help for G2Na antibody production.
Subject(s)
Antigens, Bacterial/immunology , Bacterial Proteins/immunology , HN Protein , Peptide Fragments/immunology , Respiratory Syncytial Viruses/immunology , Serum Albumin/metabolism , Vaccines, Synthetic/immunology , Viral Proteins/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Bacterial Proteins/metabolism , Female , Immunoglobulin G/blood , Immunoglobulin G/classification , Mice , Mice, Inbred BALB C , Viral Envelope ProteinsABSTRACT
Klebsiella pneumoniae OmpA, the 40-kDa major protein of the outer membrane, was cloned and expressed in Escherichia coli. The recombinant protein was produced intracellularly in E. coli as inclusion bodies. Fusion of a short peptide to the N-terminus of native P40 facilitated high-level expression of the recombinant protein. Purified recombinant P40 was analyzed to verify purity and structural integrity. The molecular mass of purified recombinant P40 determined by electrospray mass spectrometry was 37,061 Da, in agreement with the theoretical mass deduced from the DNA sequence. Specific proliferation of recombinant-P40-primed murine lymph node cells in response to recombinant P40 stimulation in vitro indicated the presence of a T-cell epitope on recombinant P40. The induction of high serum antibody titers to a synthetic peptide derived from the attachment protein G of the respiratory syncytial virus when chemically coupled to recombinant P40 indicated that the protein had potent carrier properties.
Subject(s)
Antigens/metabolism , Bacterial Outer Membrane Proteins/immunology , Klebsiella pneumoniae/metabolism , Lymphocyte Activation , Recombinant Proteins/immunology , T-Lymphocytes/immunology , Amino Acid Sequence , Animals , Antigens/chemistry , Bacterial Outer Membrane Proteins/chemistry , Bacterial Outer Membrane Proteins/isolation & purification , Bacterial Outer Membrane Proteins/pharmacology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , Carrier Proteins , Cloning, Molecular , Electrophoresis, Polyacrylamide Gel , Escherichia coli/metabolism , Female , Glutaral , Inclusion Bodies/metabolism , Klebsiella pneumoniae/genetics , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Recombinant Fusion Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology , Spectrometry, Mass, Secondary IonABSTRACT
By employing a novel biotin- and PCR-assisted capture method, which allows determination of unknown sequences on chromosomal DNA, the gene for the outer membrane protein A (OmpA) of Klebsiella pneumoniae has been isolated and sequenced to completion. The method involves linear amplification of DNA from a biotinylated primer annealing to a region with known sequence. After capture of the amplified single-stranded DNA on to paramagnetic beads, unspecifically annealing primers, i.e. arbitrary primers, were used to generate sequences with only partly determined nt sequences. The homology of the sequenced gene to ompA of related bacteria is discussed, and the gene fragment was assembled for intracellular expression in Escherichia coli, and two different fusion proteins were produced and recovered with good yields. The importance of the novel chromosomal sequencing method for gene isolation in general and the potential use of the OmpA fusion proteins are discussed.